NASDAQ:ACRS
Aclaris Therapeutics Stock News
$1.23
+0 (+0%)
At Close: Apr 18, 2024
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
10:50am, Tuesday, 19'th Jan 2021
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
10:44am, Tuesday, 19'th Jan 2021
Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares more than doubled to start out the week after the company announced positive results from its midstage rheumatoid arthritis (RA) study.
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
07:00am, Tuesday, 15'th Dec 2020
WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
04:01pm, Monday, 16'th Nov 2020
WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
07:00am, Wednesday, 04'th Nov 2020
WAYNE, Pa., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics Inc (NASDAQ:ACRS) Expected to Post Earnings of -$0.26 Per Share
07:14am, Saturday, 22'nd Aug 2020
Equities analysts expect that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post earnings per share of ($0.26) for the current quarter, according to Zacks. Three analysts have made estimates for Aclaris
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
04:00pm, Thursday, 13'th Aug 2020
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Friday, 07'th Aug 2020
Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
11:00am, Friday, 07'th Aug 2020
•First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis •First Subject Dosed in Phase 2a T
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
04:30pm, Thursday, 06'th Aug 2020
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACTIA : Chiffre d’affaires du 2ème trimestre 2020
12:00am, Wednesday, 05'th Aug 2020
Regulatory News: ACTIA (Paris:ATI) : IFRS, en M€ 2020* 2019 Var. 1er trimestre 117,1 134,4 <12,8%> 2ème trimestre 84,9 129,8 <34,6%> dont
42% of Americans Feel Uncomfortable Paying Out-of-Pocket for Chronic Pain Treatment, ATI Physical Therapy National Survey Finds
04:55pm, Tuesday, 04'th Aug 2020Allegheny Technologies Inc (ATI) Q2 2020 Earnings Call Transcript | The Motley Fool
04:30pm, Tuesday, 04'th Aug 2020
ATI earnings call for the period ending June 30, 2020.
Aclaris Therapeutics Inc (NASDAQ:ACRS) Short Interest Down 9.5% in July
03:46am, Tuesday, 04'th Aug 2020
Aclaris Therapeutics Inc (NASDAQ:ACRS) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 1,240,000 shares, a decrease of 9.5% from
ATI Announces Second Quarter 2020 Results
12:00am, Tuesday, 04'th Aug 2020
ATI Announces Second Quarter 2020 Results
